prikaz prve stranice dokumenta Retrospective Analysis of the Effectiveness and Tolerability of Long-Acting Paliperidone Palmitate Antipsychotic in Adolescent First- Episode Schizophrenia Patients
Rad nije dostupan
Znanstveni rad - Izvorni znanstveni rad
Retrospective Analysis of the Effectiveness and Tolerability of Long-Acting Paliperidone Palmitate Antipsychotic in Adolescent First- Episode Schizophrenia Patients
Journal of Child and Adolescent Psychopharmacology, 29 (2019), 3; 197-204. https://doi.org/10.1089/cap.2018.0044
Petrić, Daniela; Rački, Valentino; Gačo, Nadija; Kaštelan, Ana; Graovac, Mirjana

Institucijski repozitorij: Repozitorij Medicinskog fakulteta u Rijeci

Citirajte ovaj rad

Petrić, D., Rački, V., Gačo, N., Kaštelan, A. i Graovac, M. (2019). Retrospective Analysis of the Effectiveness and Tolerability of Long-Acting Paliperidone Palmitate Antipsychotic in Adolescent First- Episode Schizophrenia Patients. Journal of Child and Adolescent Psychopharmacology, 29. (3), 197-204. doi: 10.1089/cap.2018.0044

Petrić, Daniela, et al. "Retrospective Analysis of the Effectiveness and Tolerability of Long-Acting Paliperidone Palmitate Antipsychotic in Adolescent First- Episode Schizophrenia Patients." Journal of Child and Adolescent Psychopharmacology, vol. 29, br. 3, 2019, str. 197-204. https://doi.org/10.1089/cap.2018.0044

Petrić, Daniela, Valentino Rački, Nadija Gačo, Ana Kaštelan i Mirjana Graovac. "Retrospective Analysis of the Effectiveness and Tolerability of Long-Acting Paliperidone Palmitate Antipsychotic in Adolescent First- Episode Schizophrenia Patients." Journal of Child and Adolescent Psychopharmacology 29, br. 3 (2019): 197-204. https://doi.org/10.1089/cap.2018.0044

Petrić, D., et al. (2019) 'Retrospective Analysis of the Effectiveness and Tolerability of Long-Acting Paliperidone Palmitate Antipsychotic in Adolescent First- Episode Schizophrenia Patients', Journal of Child and Adolescent Psychopharmacology, 29(3), str. 197-204. doi: 10.1089/cap.2018.0044

Petrić D, Rački V, Gačo N, Kaštelan A, Graovac M. Retrospective Analysis of the Effectiveness and Tolerability of Long-Acting Paliperidone Palmitate Antipsychotic in Adolescent First- Episode Schizophrenia Patients. Journal of Child and Adolescent Psychopharmacology [Internet]. 2019. [pristupljeno 09.11.2024.];29(3):197-204. doi: 10.1089/cap.2018.0044

D. Petrić, V. Rački, N. Gačo, A. Kaštelan i M. Graovac, "Retrospective Analysis of the Effectiveness and Tolerability of Long-Acting Paliperidone Palmitate Antipsychotic in Adolescent First- Episode Schizophrenia Patients", Journal of Child and Adolescent Psychopharmacology, vol. 29, br. 3, str. 197-204, 2019. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:454838. [Citirano: 09.11.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:184:454838
Podaci o radu
Naslov (engleski)Retrospective Analysis of the Effectiveness and Tolerability of Long-Acting Paliperidone Palmitate Antipsychotic in Adolescent First- Episode Schizophrenia Patients
AutorDaniela Petrić
AutorValentino Rački
AutorNadija Gačo
AutorAna Kaštelan
AutorMirjana Graovac
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Katedra za fiziologiju, imunologiju i patofiziologiju)
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Katedra za psihijatriju i psihološku medicinu)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Temeljne medicinske znanosti
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Sažetak (engleski)
OBJECTIVE: The aim of this study was to explore the effectiveness and tolerability of long- acting paliperidone palmitate antipsychotic in adolescent first-episode schizophrenia patients while comparing the results with the oral antipsychotic risperidone. METHODS: This study is a retrospective, noninterventional study to assess the effectiveness and tolerability of long-acting injectable antipsychotic paliperidone palmitate in first-episode adolescent patients during the first 12 months of treatment compared with the oral antipsychotic risperidone. The data include general sociodemographic characteristics, number of hospitalizations, side effects, and the following clinical scales: Positive and Negative Syndrome Scale (PANSS), Personal and Social Performance Scale (PSP), Clinical Global Impression Improvement and Severity (CGI-I and CGI-S), and Treatment Satisfaction Questionnaire for Medication (TSQM). RESULTS: During the 12- month study period significant improvement was registered in patients receiving both paliperidone palmitate and risperidone in the following scales: PANSS, PSP, CGI-I, and CGI-S. Patients receiving paliperidone palmitate had significantly greater improvement in PANSS, CGI- S, and PSP compared with the risperidone group. Patients receiving risperidone had significantly higher number of hospitalizations than the patients receiving paliperidone palmitate. The TSQM revealed that the patients who were receiving paliperidone palmitate achieved significantly higher scores on the convenience scale, global satisfaction, and on the overall result, whereas no difference was observed on the effectiveness scale. There were several side effects reported for paliperidone (5.5% hyperprolactinemia, 5.5% weight gain) and risperidone (5.5% hyperprolactinemia, 16.7% weight gain). CONCLUSIONS: In conclusion, paliperidone palmitate seems to be safe and effective in adolescent patients. Furthermore, it compared favorably with risperidone in the clinical response, side effects, and hospitalizations.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaJournal of Child and Adolescent Psychopharmacology
Brojčani podacivol. 29, br. 3, str. 197-204
p-ISSN1044-5463
DOIhttps://doi.org/10.1089/cap.2018.0044
URN:NBNurn:nbn:hr:184:454838
Datum objave publikacije2019
URL dokumentahttp://bib.irb.hr/1000322
Vrsta resursaTekst
Prava pristupaZatvoreni pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2022-03-08 12:27:00